(HNST) Honest - Overview
Stock: Diapers, Wipes, Skincare, Makeup, Vitamins
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 62.6% |
| Relative Tail Risk | -19.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.28 |
| Alpha | -85.84 |
| Character TTM | |
|---|---|
| Beta | 1.582 |
| Beta Downside | 1.597 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.98% |
| CAGR/Max DD | -0.10 |
Description: HNST Honest December 27, 2025
The Honest Company (NASDAQ: HNST) designs, manufactures, and markets a broad portfolio of consumer-goods ranging from diapers, wipes, and baby-care essentials to skin-care, personal-care, and wellness products such as vitamins and supplements. Its distribution mix combines direct-to-consumer digital channels (company website and third-party e-commerce platforms) with traditional brick-and-mortar retail partners.
Key recent metrics (FY 2023) show revenue of approximately $1.0 billion, a year-over-year increase of ~7% driven primarily by e-commerce growth (≈15% YoY) and a modest improvement in gross margin to 45% after a cost-optimization program. The company’s “clean-beauty” positioning aligns with a sector-wide shift toward sustainably sourced, non-toxic personal-care products, a trend that the Personal Care Products sub-industry is seeing average sales-growth of 4-5% annually (S&P Global data, 2024).
Looking ahead, Honest’s performance will be sensitive to consumer discretionary spending trends, raw-material cost volatility (e.g., pulp and petrochemical inputs), and competitive pressure from both legacy brands (e.g., Procter & Gamble) and fast-growing DTC entrants. Investors should monitor the company’s ability to sustain its e-commerce momentum while expanding retail shelf-share.
For a deeper quantitative comparison, explore the analyst tools on ValueRay to benchmark HNST against peers.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 7.07m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -22.27 > 1.0 |
| NWC/Revenue: 44.71% < 20% (prev 30.73%; Δ 13.98% < -1%) |
| CFO/TA -0.09 > 3% & CFO -21.0m > Net Income 7.07m |
| Net Debt (-65.0m) to EBITDA (19.5m): -3.33 < 3 |
| Current Ratio: 4.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.7m) vs 12m ago 8.72% < -2% |
| Gross Margin: 38.81% > 18% (prev 0.37%; Δ 3844 % > 0.5%) |
| Asset Turnover: 170.0% > 50% (prev 176.3%; Δ -6.28% > 0%) |
| Interest Coverage Ratio: 2.01 > 6 (EBITDA TTM 19.5m / Interest Expense TTM 2.60m) |
Altman Z'' -11.39
| A: 0.71 (Total Current Assets 216.2m - Total Current Liabilities 44.9m) / Total Assets 241.5m |
| B: -1.98 (Retained Earnings -477.3m / Total Assets 241.5m) |
| C: 0.02 (EBIT TTM 5.23m / Avg Total Assets 225.4m) |
| D: -9.29 (Book Value of Equity -477.3m / Total Liabilities 51.4m) |
| Altman-Z'' Score: -11.39 = D |
Beneish M -3.02
| DSRI: 1.15 (Receivables 43.3m/36.2m, Revenue 383.1m/368.8m) |
| GMI: 0.95 (GM 38.81% / 36.91%) |
| AQI: 0.62 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 1.04 (Revenue 383.1m / 368.8m) |
| TATA: 0.12 (NI 7.07m - CFO -21.0m) / TA 241.5m) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of HNST shares?
Over the past week, the price has changed by -7.29%, over one month by -13.26%, over three months by -1.72% and over the past year by -62.88%.
Is HNST a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HNST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.9 | 69% |
| Analysts Target Price | 3.9 | 69% |
| ValueRay Target Price | 2 | -13.1% |
HNST Fundamental Data Overview February 03, 2026
P/E Forward = 23.2558
P/S = 0.7207
P/B = 1.4342
Revenue TTM = 383.1m USD
EBIT TTM = 5.23m USD
EBITDA TTM = 19.5m USD
Long Term Debt = 15.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.54m USD (from shortTermDebt, last fiscal year)
Debt = 6.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -65.0m USD (from netDebt column, last quarter)
Enterprise Value = 211.2m USD (276.1m + Debt 6.48m - CCE 71.5m)
Interest Coverage Ratio = 2.01 (Ebit TTM 5.23m / Interest Expense TTM 2.60m)
EV/FCF = -9.77x (Enterprise Value 211.2m / FCF TTM -21.6m)
FCF Yield = -10.24% (FCF TTM -21.6m / Enterprise Value 211.2m)
FCF Margin = -5.64% (FCF TTM -21.6m / Revenue TTM 383.1m)
Net Margin = 1.85% (Net Income TTM 7.07m / Revenue TTM 383.1m)
Gross Margin = 38.81% ((Revenue TTM 383.1m - Cost of Revenue TTM 234.4m) / Revenue TTM)
Gross Margin QoQ = 37.26% (prev 40.39%)
Tobins Q-Ratio = 0.87 (Enterprise Value 211.2m / Total Assets 241.5m)
Interest Expense / Debt = 8.56% (Interest Expense 555.0k / Debt 6.48m)
Taxrate = 12.67% (110.0k / 868.0k)
NOPAT = 4.57m (EBIT 5.23m * (1 - 12.67%))
Current Ratio = 4.82 (Total Current Assets 216.2m / Total Current Liabilities 44.9m)
Debt / Equity = 0.03 (Debt 6.48m / totalStockholderEquity, last quarter 190.2m)
Debt / EBITDA = -3.33 (Net Debt -65.0m / EBITDA 19.5m)
Debt / FCF = 3.01 (negative FCF - burning cash) (Net Debt -65.0m / FCF TTM -21.6m)
Total Stockholder Equity = 183.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 7.07m / Total Assets 241.5m)
RoE = 3.87% (Net Income TTM 7.07m / Total Stockholder Equity 183.0m)
RoCE = 2.64% (EBIT 5.23m / Capital Employed (Equity 183.0m + L.T.Debt 15.4m))
RoIC = 2.50% (NOPAT 4.57m / Invested Capital 183.0m)
WACC = 11.65% (E(276.1m)/V(282.6m) * Re(11.75%) + D(6.48m)/V(282.6m) * Rd(8.56%) * (1-Tc(0.13)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.51%
Fair Price DCF = unknown (Cash Flow -21.6m)
EPS Correlation: 84.02 | EPS CAGR: 49.95% | SUE: -0.71 | # QB: 0
Revenue Correlation: 85.49 | Revenue CAGR: 3.84% | SUE: -2.86 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.09 | Chg30d=-0.009 | Revisions Net=-1 | Growth EPS=-29.5% | Growth Revenue=-9.1%